BioSpace News Archive

Optinose today announced preliminary XHANCE ® (fluticasone propionate) net product revenue of $19.5 million for the three months ended June 30, 2023.

InMode Ltd. today announced its consolidated financial results for the second quarter ended June 30, 2023.

Biohaven Ltd. (NYSE: BHVN) (“Biohaven” or the “Company”) today announced multiple updates on key programs including: preliminary EEG data from its lead investigational agent, BHV-7000, from the Kv7 activator program; Phase 1 update on its brain-penetrant dual TYK2/JAK1 inhibitor, BHV-8000; development update on its IgG degrader, BHV-1300, from the bispecific platform; and a regulatory update on troriluzole.

Carmell Therapeutics Corporation (Nasdaq: CTCX) (“Carmell”), a regenerative medicine company today announced the execution of a definitive agreement and plan of merger (the “Merger Agreement”) with Flagstaff-based Axolotl Biologix, a profitable regenerative medicine company developing products for active soft tissue repair, aesthetics and orthopedic indications (“Axolotl”).

Novocure today reported financial results for the quarter ended June 30, 2023.

High-level results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful progression-free survival (PFS) and overall survival (OS) in previously treated patients across multiple HER2-expressing advanced solid tumors, two secondary endpoints of the trial.

Cessation Therapeutics Announces Food and Drug Administration Authorization for First-in-Human Clinical Trial of Antibody for Prevention of Fentanyl Overdose.

NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, announced today that the Molecular Diagnostics Services Program (MolDx) has conveyed coverage for the RaDaR assay, a personalized liquid biopsy for minimal residual disease (MRD) and recurrence detection.

Marinus Pharmaceuticals, Inc. today announced that it plans to release financial results for the second quarter ended June 30, 2023 on August 10, 2023.

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2023.